Generate Biomedicines Q2 net loss $67.3M; Phase 3 asthma studies advancing, cash $457.4M

Generate Biomedicines, Inc.

2026-Q2 EPS reported -$1.41 revenue$13,538,000

Revenue $6.3M (down from $10.1M YoY); net loss $67.3M vs $56.7M YoY; cash $457.4M (down from $516.6M Q1).
Phase 3 SOLAIRIA-1/2 for GB-0895 (anti-TSLP) in severe asthma recruiting in 33 countries; Phase 1b COPD data at ERS Sept 8.
Phase 1 for GB-4362 (MMAE neutralizer) dosed first cohort; FDA Fast Track for urothelial cancer toxicity reduction.
Novartis advanced a biologic designed with Generate's platform into preclinical pipeline; first AI-enabled biologic to reach this stage.
GB-5267 CAR T Phase 1 recruiting for ovarian cancer; first patient expected in 2026; cash runway into H1 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.